Insulet (PODD) revenue

Revenue · fiscal 2025
$2.71B

Insulet (PODD) reported revenue of $2.71B in fiscal 2025 (the year ended December 31, 2025). That is 30.7% higher than the $2.07B of fiscal 2024. Figures as of 18 Nov 2026, 10:28 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$2.71B
Change on fiscal 2024
+30.7%
Growth, 5 years
+24.5% a year
Growth, 10 years
+26.2% a year
Highest on record
$2.71Bfiscal 2025
Lowest on record
$66.03Mfiscal 2009
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Insulet revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 24.5% a year; over ten years the rate was 26.2% a year. Across the 17 fiscal years on record (2009–2025), the highest was $2.71B in fiscal 2025 and the lowest $66.03M in fiscal 2009.

History · 17 fiscal years

Revenue by fiscal year

Insulet revenue, year by year

Insulet (PODD) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$2.71B 30.7% up
2024$2.07B 22.1% up
2023$1.70B 30.0% up
2022$1.31B 25.4% up
2021$1.04B 15.1% up
2020$904.40M 22.5% up
2019$738.20M 30.9% up
2018$563.80M 21.6% up
2017$463.80M 26.4% up
2016$366.99M 39.1% up
2015$263.89M 14.1% up
2014$231.32M 6.4% down
2013$247.08M 16.9% up
2012$211.37M 38.8% up
2011$152.26M 57.0% up
2010$96.97M 46.8% up
2009$66.03M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Insulet and comparable companies
CompanyRevenueFiscal year
Bio-Rad Laboratories BIO$2.58B2025
Molina Healthcare MOH$45.43B2025
Spyre Therapeutics SYRE$886.00K2023
Qiagen QGEN$2.09B2025
Insulet PODD$2.71B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PODD

Insulet, figure by figure

Insulet (PODD) overview: price, valuation and scorecardAll health care companies by market value

Insulet revenue: questions and answers

What is Insulet's revenue?

Insulet (PODD) reported revenue of $2.71B in fiscal 2025 (the year ended December 31, 2025). That is 30.7% higher than the $2.07B of fiscal 2024.

What is the growth rate of Insulet's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 24.5% a year; over ten years the rate was 26.2% a year.

What are the highest and lowest revenue figures on record for Insulet?

Across the 17 fiscal years on record (2009–2025), the highest was $2.71B in fiscal 2025 and the lowest $66.03M in fiscal 2009.

How is Insulet's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Insulet it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Insulet (PODD) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/PODD/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.